Last reviewed · How we verify
The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of the research study is to learn whether external beam radiation can be used as a safe and effective treatment for patients with bulky (≥ 5cm) sites of non-Hodgkin's lymphoma prior to treatment with 90Y-ibritumomab tiuxetan (Zevalin).
Details
| Lead sponsor | The Cleveland Clinic |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 12 |
| Start date | 2005-12 |
| Completion | 2010-06 |
Conditions
- Lymphoma, B-Cell
Interventions
- external beam radiotherapy plus 90-Y ibritumomab tiuxetan
Primary outcomes
- PET and CT (w/oral and IV contrast) — 90 days after treatment
Countries
United States